Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 102

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 102
---
 licenses may not be available or may not be available on commercially reasonable terms.

A third party may hold intellectual
property rights, including patent rights, that are important or necessary to the development or manufacture of our product candidates.
It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in
which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable
terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially
reasonable terms, our business could be harmed.

Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.

If we initiate legal proceedings
against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering
our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity
or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or
abroad, even outside the context of litigation. Such mechanisms include inter partesreview, ex partere-examination and
post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings).
Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product
candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect
to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel
and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity
and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss
of patent protection could have a material adverse impact on our business.

Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other